Abstracts tagged "etoricoxib and treatment"

Abstract Number: 2440 • 2013 ACR/ARHP Annual Meeting
Is There a Role For Etoricoxib In Patients With Axial Ankylosing spondylitis Refractory To Traditional NSAID?
Maria García Manrique¹, Pilar Font², Joan Calvet³, María Cruz Fernandez⁴, Carlos Montilla⁵, Luis Linares⁶, Elia Brito⁷, Xavier Juanola⁸, Juan Mulero⁹, Rubén Queiro¹⁰, Rosa M. Morla¹¹, Rosario Garcia-Vicuña¹², Alba Erra¹³, Mireia Moreno¹⁴, Marta Larrosa¹⁵, Eduardo Collantes¹⁶ and Jordi Gratacos¹⁷, ¹Rheumatology, Hospital Parc Taulí, Sabadell, Spain, ²Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ³Rheumatology, Corporació Sanitària Parc Taulí, Sabadell, Spain, ⁴Rheumatology, Hospital General de Móstoles, Mostoles, Spain, ⁵Rheumatology Service, Hospital Universitario de Salamanca, Salamanca, Spain, ⁶Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ⁷Rheumatology, Hospital Ramón y Cajal, Madrid, Spain, ⁸Rheumatology, University Hospital Bellvitge, Barcelona, Spain, ⁹Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain, ¹⁰Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ¹¹Rheumatology, Hospital Sta Tecla, Tarragona, Spain, ¹²Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹³Hospital de Sant Rafael, Barcelona, Spain, ¹⁴Rheumatology, Hospital Universitari Parc Taulí, Sabadell, Spain, ¹⁵Rheumatology, Hospital Universitari Parc Tauli, Sabadell, Spain, ¹⁶Rheumatology, Hospital Reina Sofia, Cordoba, Spain, ¹⁷Rheumatology Service, Hospital Universitari Parc Taulí, Sabadell (Barcelona), Spain
Background/Purpose: Anti-TNF treatment has demonstrated its effectiveness in axial ankylosing spondylitis (AS) patients with inadecuate response to traditional NSAIDs (tNSAIDs) therapy (>=2 tNSAIDs), but also aspects…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].